Neonatal hypoxia-ischaemia (HI) is the most common cause of death and disability in
human neonates, and is often associated with persistent motor, sensory, and cognitive …

Blood–brain barrier (BBB) disruption, mediated through matrix metalloproteinases (MMPs)
and other mechanisms, is a critical event during ischemic stroke. Tissue plasminogen …

The regulation of cerebrovascular permeability is critical for normal brain homeostasis, and
the “breakdown” of the blood-brain barrier (BBB) is associated with the development of …

Thrombolytic treatment of ischemic stroke with tissue plasminogen activator (tPA) is
markedly limited owing to concerns about hemorrhagic complications and the requirement …

The paraoxonase (PON) gene cluster contains at least three members, including PON1,
PON2, and PON3, located on chromosome 7q21. 3–22.1. Until now there has been little …

Nanotechnology is an area of growing public interest. Its attractiveness stems from the
promise offered socially and economically by the recent significant advances in …

Tissue plasminogen activator (tPA), a fibrin specific activator for the conversion of
plasminogen to plasmin, stimulates thrombolysis and rescues ischemic brain by restoring …

Today there exists only one FDA-approved treatment for ischemic stroke; ie, the serine
protease tissue-type plasminogen activator (tPA). In the aftermath of the failed stroke clinical …

Brain hemorrhage is a serious complication of tissue plasminogen activator (tPA) therapy for
ischemic stroke. Here we report that activated protein C (APC), a plasma serine protease …

Tissue plasminogen activator (tPA) is the only therapeutic agent approved to treat patients
with acute ischemic stroke. The clinical benefits of tPA manifest when the agent is …